Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...
Andon Health’s COVID-19 Trio Test Kit and OTC Antigen Test Win FDA Approval
Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that...
Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that...
Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study
Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...
Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
Simcere Pharma’s Anti-Insomnia Drug Daridorexant Meets Primary Endpoint in Phase III Clinical Trial
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced topline results from a Phase III...
ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of Timdarpacept in CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...
MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based...
FDA Extends Indication for BMS’ CAR-T Therapy Breyanzi to Include Relapsed MCL in Adults
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...
Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China
Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...
Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development
Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin...
Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...
Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases,...
Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...